Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 13NETWORK 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 13Gastrointestinal 9Breast 9Other hematologic neoplasm 7Thoracic 6Plasma cell 6Lymphoid 5Tumor-Agnostic 4Head & Neck 4Gynecologic 4CNS 4Dermatologic 2Sarcoma 1Other solid neoplasm 1Myeloid 1Classical hematology 1

Conditions

Advanced/Metastatic Solid Tumors 1

Interventions

Injections 98pembrolizumab 90Carboplatin 57Paclitaxel 54Cisplatin 52Nivolumab 44Docetaxel 43Pemetrexed 42Gemcitabine 37atezolizumab 32tislelizumab 29Bevacizumab 29toripalimab 23Fluorouracil 23Capecitabine 23Irinotecan 22Oxaliplatin 20durvalumab 19Ipilimumab 18Leucovorin 17Cetuximab 17Rifampin 14Itraconazole 14olaparib 13spartalizumab 12Midazolam 12Cyclophosphamide 12trifluridine tipiracil drug combination 11sintilimab 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Standard of Care × Other solid neoplasm × Clear all
NCT05405595 2026-01-07

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Adagene Inc

Phase 1/2 Recruiting
186 enrolled
Other solid neoplasm

Advanced/Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡